CytomX Therapeutics (CTMX) Return on Invested Capital (2016 - 2026)

CytomX Therapeutics has reported Return on Invested Capital for 9 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital fell 3.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (down 3.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.03% in Q1 2025, with the low at 0.02% in Q4 2024.
• Historically, Return on Invested Capital has averaged 0.0% across 4 years, with a median of 0.0% in 2025.
• Annual changes were most pronounced in 2025 — Return on Invested Capital increased 3 bps — and 2026, when it fell 3 bps.
• CytomX Therapeutics' Return on Invested Capital stood at 0.0% in 2023, then slumped by 9128 bps to 0.02% in 2024, then surged by 98 bps to 0.0% in 2025, then sank by 522 bps to 0.0% in 2026.
• The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.